This promotional material is intended for UK Healthcare Professionals (HCPs) who have attended a Produodopa (foslevodopa/foscarbidopa) overview training meeting and are involved in the overall care and maintenance of patients who have already been prescribed Produodopa. Adverse event reporting information can be found below.
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Welcome to the PRODUODOPA training resources site
This website is designed to provide resources exclusively for UK healthcare professionals (HCPs) who have attended a Produodopa Therapy Overview and Ongoing Management training course. It is for HCPs who are involved in the overall care and maintenance of patients who have already been prescribed and optimised on Produodopa and are not involved in treatment or prescribing decisions. Any clinical considerations should be referred back to the treating HCP.
The materials provided on this site are supplementary to the SmPC, Patient Information Leaflet (PIL) and the Instructions for Use, but do not replace them. Please refer to the SmPC for further information. The SmPC and the PIL can be found online at www.medicines.org.uk [link will take you to a third party website, not controlled by AbbVie].
These materials have been developed and funded by AbbVie. You must not copy, share, or distribute these materials except as permitted by AbbVie Ltd.
Resources for your patients
Patients prescribed with PRODUODOPA should receive a Patient Welcome Pack. Use the links provided below to access patient materials that may be beneficial for referencing in your routine clinical practice. Your patients will have access to these materials when they receive their welcome pack.
The information in the Patient Welcome Pack is supplementary to the Patient Information Leaflet (PIL) but does not replace it. Patients should always refer to the PIL before they start PRODUODOPA treatment. Patients can find the PIL inside the product packaging or online at www.medicines.org.uk [link will take you to a third party website, not controlled by AbbVie]. Patients should speak to their healthcare professional if they have any questions about their treatment.
These materials have been developed and funded by AbbVie and are intended exclusively for the use of patients who have been prescribed PRODUODOPA by their healthcare professional. You must not copy, share, or distribute these materials except as permitted by AbbVie Ltd
Patient welcome pack
Patient booklet
All other materials listed within the Patient welcome pack should be used in conjunction with this Patient booklet and not on their own. These materials do not replace the PIL and Instructions for Use.
View the practical guide for patients, outlining how to start their treatment journey.
Travelling with PRODUODOPA pocket guide
This booklet provides information for patients on travelling with PRODUODOPA and the infusion system.
‘How to’ video
This video provides information for patients on how to administer PRODUODOPA treatment.
Infusion set up leaflet
This leaflet helps patients set up their PRODUODOPA infusion set.
Infusion site tracker
This tracker helps patients track infusion sites.
Patient support card
The patient support card is an information card intended for PRODUODOPA patients, so that they have the required contact details to hand when needed.
Please refer to the PRODUODOPA Summary of Product Characteristics (SmPC) for further information on adverse events, contraindications and special warnings and precautions for use.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-PRODD-260334. Date of preparation: August 2026.
